ClinicalTrials.gg
RecruitingNCT07387185Updated Feb 4, 2026

AI System for Detection and Characterization of Chronic Enteropathies

An observational study in Celiac Disease, Small Bowel Mucosal Atrophy or Lesions and Non-celiac Enteropathies, sponsored by Istituti Clinici Scientifici Maugeri SpA. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Istituti Clinici Scientifici Maugeri SpA · Observational

How we know · 2 judgments

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
380
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Celiac Disease with a site in Italy — 14 open to participants now, 16 under way, none of them phase 3. Celiac Disease · Italy.

Planned enrollment
7th of 26
380 · median 207
Started
2025
with 3 others
Observational
26 of 61
9 open now
Primary completion
2028-03
later than 14 of 15 live
Registered
57th of 61
by date
Lead sponsor
2 of 61
Istituti Clinici Scientifici Maugeri SpA

Among the 61 studies in Celiac Disease with a site in Italy, this one is the 7th largest by planned enrollment of the 26 observational ones that give a count, is one of 4 that started in 2025, is one of 26 observational ones, reaches primary completion later than 14 of the 15 other live ones, and was the 57th registered.

Celiac Disease

353 studies on the registry are indexed under Celiac Disease; 78 are open to participants now.

Browse Celiac Disease studies →

Open to participants now

14 of the 61 studies in Celiac Disease with a site in Italy are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Celiac Disease with a site in Italy, or all of them as a file.
02

Study summary

Coeliac disease (CD) is an immune-mediated enteropathy leading to small intestinal mucosal atrophy. Diagnosis relies on serology and duodenal biopsies, but it can be complicated by patchy lesions and differential diagnosis with Non-Celiac Enteropathies (NCEs). This multicenter observational study aims to develop and validate an Artificial Intelligence (AI) system to detect and characterize small bowel mucosal atrophy and other pathological findings using endoscopic imaging. The study involves a retrospective phase for training the AI model and a prospective phase to validate its diagnostic accuracy compared to standard human assessment.

Read the detailed description

The study is a multicenter observational non-profit study with a total expected duration of 36 months. It aims to address the challenges in diagnosing CD and NCEs, specifically the subjective nature of endoscopic evaluation and inter-observer variability.

The study proceeds in two phases:

  1. Model Development (Retrospective): Training of Deep Learning algorithms on anonymized endoscopic images/videos to identify mucosal atrophy and other lesions (e.g., angiodysplasia, ulcers, polyps).
  2. Validation (Prospective): Enrolling patients undergoing small bowel endoscopy to validate the AI system's performance.

The system aims to provide analysis to assist endoscopists, reducing missed lesions and improving diagnostic accuracy.

Validation of the AI system will be performed offline on recorded anonymized endoscopy videos collected prospectively during the validation phase.

03

Conditions studied

  • Celiac Disease
  • Small Bowel Mucosal Atrophy or Lesions
  • Non-celiac Enteropathies

Browse trials for

Keywords

  • Artificial Intelligence
  • Endoscopy
  • Deep Learning
  • Computer-Aided Diagnosis
  • Small Bowel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients undergoing endoscopic investigation of the small bowel (endoscopy or capsule endoscopy) for suspected or known celiac disease, non-celiac enteropathies or other small bowel conditions

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (age ≥18 years).
  • Patients undergoing endoscopic investigation of the small bowel (endoscopy or capsule endoscopy)

Exclusion criteria

Exclusion Criteria:

  • Inability to provide .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
380 participants (estimated)
Patient registry
No

Groups and cohorts

  • Enteropathy Cohort (CD/NCE)

    Adult patients (\>=18 years) with suspected or confirmed Celiac Disease or Non-Celiac Enteropathies undergoing small bowel endoscopy.

  • Control Cohort

    Adult patients (\>=18 years) undergoing small bowel endoscopy who do not have enteropathy or other small bowel pathological lesions (negative controls).

  • Other Small Bowel Lesion Cohort

    Adult patients (\>=18 years) undergoing small bowel endoscopy who who do not have Celiac Disease or Non-Celiac Enteropathies but have other small bowel pathological lesions.

06

What researchers measure

Primary outcomes

  1. Diagnostic Performance of the AI System

    Evaluation of Accuracy, Sensitivity, and Specificity of the AI system in detecting intestinal mucosal atrophy and other major pathological findings compared to the gold standard (histology/expert consensus).

    Time frame: Through study completion (36 months)

Secondary outcomes

  1. Comparison of Diagnostic Performance (No AI-assistance vs AI-assisted)

    Comparison of accuracy, sensitivity, and specificity of gastroenterologists performing assessment with and without the assistance of the AI system.

    Time frame: Through study completion (36 months)

  2. Inter-observer Agreement

    Measurement of agreement between the AI system and expert gastroenterologists in evaluating the extent of mucosal atrophy.

    Time frame: Through study completion (36 months)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Mar 2028, 36 months after the start.

Of 48 observational studies under Celiac Disease, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 83. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Feb 4, 2026
StartActual
Feb 20, 2025
Primary completionEst.
Mar 1, 2028
CompletionEst.
Mar 1, 2028
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07387185
Collaborators
Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Valduce Hospital, Azienda Ospedale Università Padova, Padova, IRCCS Azienda Ospedaliero-Universitaria di Bologna, ASST Cremona, Cremona, A.O.U. Città della Salute e della Scienza, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Asst Degli Spedali Civili Di Brescia, IRCCS Policlinico San Donato, Milano, Azienda Socio-Sanitaria Territoriale (ASST) di Pavia, Azienda Unità Sanitaria Locale della Romagna, ASST Lecco, Lecco, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policinico, Milano, Academic Unit of Gastroenterology, Sheffield Teaching Hospitals, Sheffield, UK
Responsible party
Sponsor
First posted
Feb 4, 2026
Start date
Feb 20, 2025
Primary completion
Mar 1, 2028 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Feb 4, 2026

Study contacts

Federico Biagi, MD
Contact
federico.biagi@icsmaugeri.it
0382592695 ext. +39

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion